Quantum-Si Pushed Proteus Launch Into 2027
The protein-sequencing company announced a reduction of about 20% of its workforce alongside a later commercial launch timetable.
Quantum-Si Incorporated (QSI), a proteomics technology company, pushed the anticipated commercial launch of its Proteus protein-sequencing platform into 2027, replacing a year-end 2026 timetable it had reaffirmed in its previous two quarterly updates. The revised schedule followed reports of successful sequencing on prototype and integrated instruments, shifting the focus to additional design work before commercialization.
The company said it plans an additional integrated instrument design cycle focused on manufacturing readiness, system repeatability and the customer experience at launch. Chief Executive Officer Jeff Hawkins said testing had generated sequencing data that reinforced the company's confidence in the underlying technology. He said the additional cycle would strengthen manufacturing readiness and improve system performance, while acknowledging that the decision extended the development timeline.
The change followed a May update in which Quantum-Si had reported automated sequencing runs that combined instrumentation, its KinetIQ Array, sequencing chemistry and data analysis without user intervention after initiation. It had also sequenced its first customer samples on a Proteus prototype and begun roadshows ahead of the planned launch. Quantum-Si now says the revised timetable allows further integrated instrument testing, verification and validation, and manufacturing preparation.
Spending had increased across the three reported quarters despite the company's expense controls. Adjusted operating expenses rose from $18.3 million in the final quarter of 2025 to $21.4 million in the first quarter of 2026 and $22.6 million in the second. Total second-quarter operating expenses were $25.8 million. The company attributed spending levels to continued investment in Proteus development and commercialization readiness, partially offset by expense management.
Quantum-Si expects the workforce reduction and other cost-management actions to generate approximately $12 million in annualized operating expense savings once fully implemented. The company said the actions are intended to align spending with the revised launch schedule while preserving resources for critical development, manufacturing and commercial readiness activities.
Second-quarter revenue was $344 thousand, compared with $591 thousand a year earlier. Quantum-Si attributed the decline to its transition from Platinum to Proteus, including lower instrument demand, continued consumable usage by existing customers and commercial programs supporting customer migration.
Gross margin improved to 50% from 29% in the first quarter. Second-quarter product revenue was $314 thousand, while service revenue was $30 thousand. Quantum-Si recorded a quarterly net loss of $23.5 million, or $0.11 a share.
The launch delay did not alter the company's financial guidance for the full year. Quantum-Si continues to forecast approximately $1.0 million in revenue, adjusted operating expenses of $98.0 million or less and total cash usage of $93.0 million or less. The company expects revenue to continue reflecting customer purchasing behavior, installed-base consumable activity and planning for the anticipated Proteus platform.
Alongside the longer development schedule, Quantum-Si offered a broader assessment of the market it hopes to serve. Hawkins said work with customers on agricultural applications, pathogen detection and typing, and viral protein surveillance had expanded the company's view of Proteus's addressable markets. The company estimates an annual non-human proteomics opportunity exceeding $4 billion; that figure described its market assessment rather than reported sales or orders.
Quantum-Si held $169.9 million in cash, cash equivalents and marketable securities at June 30. Under the updated operating plan, the company expects that capital to fund operations into the fourth quarter of 2028, rather than the second quarter of 2028 projected in May. The company tied that extension to the announced workforce reduction and other cost-management actions accompanying the later launch.
Stronger demand supports expansion as pricing diverges